Monogram Technologies (MGRM) Q4 2024 earnings summary

Executive summary

• Ended 2024 with a cash balance of $15.7 million, higher than the previous year, due to disciplined spending and a successful $13 million preferred D-raise, including significant management investment.

• Completed all supplemental testing and submitted a formal response to the FDA's Additional Information Request for the mBôs TKA System; FDA clearance decision pending.

• Advanced strategic collaboration with Shalby Limited for clinical trials in India, including robot shipment and investigator meeting.

• Named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.

• Focused on developing a fully autonomous robotic system for knee replacements, aiming to compete with market leader Stryker’s Mako system.

Financial highlights

• Cash and cash equivalents at year-end were $15.7 million, up from the prior year.

• Monthly cash burn rate reduced to approximately $1.1 million in Q4, with an annual average near $1.2 million.

• Research and development expenses decreased 17% year-over-year to $8.8 million due to completion of verification and validation phases.

• Net loss was $16.3 million for 2024, compared to $13.7 million in 2023; prior year benefited from a $3M warrant liability gain not repeated in 2024.

• No traditional debt and limited short-term warranty obligations, providing a strong balance sheet.

Outlook and guidance

• Expect to maintain a cash burn rate near $1.1 million per month, with some higher outlays in Q2 for tooling, compliance, and clinical trial preparations.

• Sufficient cash expected through the 510(k) application process and solid cash position anticipated through 2025.

• Awaiting FDA clearance for mBôs TKA System, which would enable U.S. commercialization.

• Preparing for international clinical trials in India with Shalby Limited; exploring further domestic and international partnerships.

• Additional capital will be required for an aggressive commercial launch post-regulatory clearance.